Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Overman

Showing results (161-170 of 265) with videos related to

Pageof 27
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 19, 2024
Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluationRomain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.
Journal for Immunotherapy of Cancer|May 31, 2024
Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 studyMichael J Overman, Fabio Gelsomino, Massimo Aglietta, et al.
Cancer|March 12, 2019
Clinical and molecular characterization of early-onset colorectal cancerAlexandra N Willauer, Yusha Liu, Allan A L Pereira, et al.
Nature Reviews. Cancer|February 20, 2025
Defining a 'cells to society' research framework for appendiceal tumoursAndreana N Holowatyj, Michael J Overman, Konstantinos I Votanopoulos, et al.
British Journal of Cancer|December 24, 2014
Association between KRAS mutation and lung metastasis in advanced colorectal cancerA A L Pereira, J F M Rego, V Morris, et al.
JCO Precision Oncology|October 12, 2023
Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA TestingStefania Napolitano, Aparna R Parikh, Jason Henry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceScott Kopetz, Paulo M Hoff, Jeffrey S Morris, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancerGiacomo Mazzoli, Romain Cohen, Sara Lonardi, et al.
The Lancet. Oncology|July 24, 2017
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyMichael J Overman, Ray McDermott, Joseph L Leach, et al.
Journal of the National Cancer Institute|May 3, 2018
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal CancerJonathan M Loree, Ann M Bailey, Amber M Johnson, et al.
Pageof 27

Showing results (161-170 of 265) with videos related to

Sort By:
Pageof 27
European Journal of Cancer (Oxford, England : 1990)|January 19, 2024
Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluationRomain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.
Journal for Immunotherapy of Cancer|May 31, 2024
Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 studyMichael J Overman, Fabio Gelsomino, Massimo Aglietta, et al.
Cancer|March 12, 2019
Clinical and molecular characterization of early-onset colorectal cancerAlexandra N Willauer, Yusha Liu, Allan A L Pereira, et al.
Nature Reviews. Cancer|February 20, 2025
Defining a 'cells to society' research framework for appendiceal tumoursAndreana N Holowatyj, Michael J Overman, Konstantinos I Votanopoulos, et al.
British Journal of Cancer|December 24, 2014
Association between KRAS mutation and lung metastasis in advanced colorectal cancerA A L Pereira, J F M Rego, V Morris, et al.
JCO Precision Oncology|October 12, 2023
Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA TestingStefania Napolitano, Aparna R Parikh, Jason Henry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceScott Kopetz, Paulo M Hoff, Jeffrey S Morris, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancerGiacomo Mazzoli, Romain Cohen, Sara Lonardi, et al.
The Lancet. Oncology|July 24, 2017
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyMichael J Overman, Ray McDermott, Joseph L Leach, et al.
Journal of the National Cancer Institute|May 3, 2018
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal CancerJonathan M Loree, Ann M Bailey, Amber M Johnson, et al.
Pageof 27